Unlocking a new treatment path for resistant cancers


How to treat cancer that is resistant to immune checkpoint blockade therapy? That is what Paulien Kaptein, Daniela Thommen and colleagues focus on in a new study on immunotherapy. By targeting a powerful protein essential for activating T cells, they’ve uncovered a promising strategy that could enhance treatment outcomes for cancer patients.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.